CEO of International Medical Consultants, IMC Radiology, and CMO of Levolta Pharma

Ketan Desai, MD, PhD, is the Founder and Chief Executive Officer of IMC Radiology, the founder and Chief Medical Officer of LeVolta Pharma (biotechnology), Founder and Chairperson of Omega Skin Solutions ... more

ALL CONTRIBUTIONS

Vexing Viral Variants And Vaccination - In Vain?
Why vaccines may be overrated for COVID-19.
Read
Review Of Present Therapies For Covid-19
A summary of authorized drugs for Covid-19, those in development, and those that have failed.
Read
Pitfalls Of Biotechnology Investing
How capital distorts the availability of biotechnology companies.
Read
Whither Flexion?
A new study highlights that there are likely fewer candidates for Flexion's star osteoarthritis treatment and this could affect the stock price of Flexion considerably.
Read
Is India's Economic Potential Over-Hyped?
An examination of the culture and demographics of India in relation to its economic potential.
Read
Ford Model T And Personalized Medicine
While technology marches on, the economics of personalized medicines just don’t add up. Will they be like costly trinkets being displayed in a museum that we can watch at a distance but not own?
Read

Comments

Latest Comments
CytoDyn's Update Provides A Clear Path Towards Approval With Up-Listing Potential Still In The Cards
8 months ago

What is sad is your ignorant pumping.  Nothing was done to this stock, it went down as there was no science, no management, no clinical or regulatory path forward.  And no, it does not go to show any stock has "unknown things and is unpredictable" - I've been bearish on this for over a year while you were shamelessly pumping.  

In this article: CYDY
CytoDyn's Update Provides A Clear Path Towards Approval With Up-Listing Potential Still In The Cards
10 months ago

Still pumping this garbage?  Has failed every study, been scoled by the FDA for lying, has had 25 different firms file lawsuits, lost a distributor in US, and stock is now down to $1.40 or thereabouts. When you started pumping this stock, it was in the $4 range.  Have you no shame?

In this article: CYDY
Review Of Present Therapies For Covid-19
1 year ago

Thanks. Your point of placebo is well taken. Often though, it is not true placebo. The design is standard of care plus study drug versus standard of care plus placebo. The patients thus get the minimum of standard of care.

In this article: LLY, MRK, CYDY, REGN, HGEN, RLFTF
Review Of Present Therapies For Covid-19
1 year ago

Thanks

In this article: LLY, MRK, CYDY, REGN, HGEN, RLFTF
CytoDyn's Update Provides A Clear Path Towards Approval With Up-Listing Potential Still In The Cards
1 year ago

Written by Cytodyn insiders!! What conflict of interest!! Zero credibilty!! LOL!!!!

In this article: CYDY
CytoDyn's Update Provides A Clear Path Towards Approval With Up-Listing Potential Still In The Cards
1 year ago

What an ignorant and biased rant. Look at these reviews on the status of immune response to COVID19. These are by independent scientists who, unlike you or Cytodyn, have no conflict of interest. They are peer reviewed and are in world class journals Sciene, Lancet. CCR5 is not a pathway that anyone of repute espouses.

www.sciencedirect.com/.../S1074761320301837

science.sciencemag.org/content/369/6508/eabc8511

www.thelancet.com/.../fulltext#seccestitle60

In this article: CYDY
CytoDyn's Update Provides A Clear Path Towards Approval With Up-Listing Potential Still In The Cards
1 year ago

What a poor response. You DID NOT SHOW A SINGLE PEER REVIEWED INDEPENDENT ARTICLE ON CCR5 AND COVID19. We are not talking about HIV but COVID19. Stay on topic, will you, and stop dissembling the truth?

In this article: CYDY
CytoDyn's Update Provides A Clear Path Towards Approval With Up-Listing Potential Still In The Cards
1 year ago

Scientific knowledge that Cytodyn pumpers dont know or deliberately obfuscate - neutrophils in COVID19 are determined by CCR8, and not CCR5. See article below. Leronlimab binds CCR5, not CCR8. Which is why other than Cytodyn, NOBODY IN THE SCIENTIFIC OR PHARMA COMMUNITY trusts cytodyn data.

In this article: CYDY
CytoDyn's Update Provides A Clear Path Towards Approval With Up-Listing Potential Still In The Cards
1 year ago

Then don't respond. You must have a guilty conscience.

In this article: CYDY
1 to 10 of 23 comments
1 2 3

STOCKS I FOLLOW

ABT Abbott Laboratories
AMGN Amgen Inc.
BMY Bristol-Myers Squibb Company
MRK Merck & Co Inc.
VVUS Vivus, Inc.

TWEETS

PERSONAL BLOG

Latest Posts

Work Experience

Education

Publications

Germs of War
Ketan Desai
BookSurge Publishing
08/21/2002
A book where bioterrorism meets international intrigue, politics, and religious fundamentalism.